Shanghai Henlius Biotech reported acceptance by China’s National Medical Products Administration (NMPA) of IND applications for three differentiated solid‑tumor candidates. IND acceptance in China clears the regulatory pretrial step and allows Henlius to initiate clinical studies domestically for its oncology programs. The move underscores continued expansion of clinical oncology pipelines in Greater China and signals potential regional trial recruitment advantages and regulatory sequencing strategies. For global investors and partners, NMPA IND acceptance can increase program valuation and support subsequent global development planning.